The Oxford Academic Health Science Network gets innovation into clinical practice to improve patient safety, outcomes and experience, and generate economic growth through collaboration between the NHS, industry and universities. We cover a region of three million people living in Berkshire, Buckinghamshire, Milton Keynes and Oxfordshire. We aim to foster long term partnerships with industry, build a culture of innovation in the NHS, and have secured over £100 million of investment into the Thames Valley region. Our specialist capabilities include diagnostics and precision medicine, early innovator support and market access. You can find out more about how we can help on our website.
Find your nearest AHSN
The Oxford AHSN region has identified five local challenges; Increasing out-of-hospital care, redesigning and reducing pressure on hospital emergency services, offering more personalised care, digitally-enabled primary and outpatient care, improving outcomes by population health initiatives.
Artificial intelligence call
The UK government has recently pledged £250m for the NHS to invest in Artificial Intelligence (AI). The aim is to provide AI solutions that will transform care and reduce waiting times.
The Oxford Academic Health Science Network has extensive experience in real world evaluation projects, with the aim of gathering enough evidence to create a business case for these innovations.
MetaGuideX receive £50,000 investment through Oxford AHSN Accelerator programme
The Oxford AHSN Accelerator programme, in collaboration with BioCity and regional partners from the NHS, industry and research within the Thames Valley, offers a launchpad for entrepreneurs and their ventures to move from idea to market. MetaGuideX won a place on the intensive eight-week programme and pitched to investors on the final day of the Accelerator programme in November 2020.
Johnson & Johnson and Oxford AHSN cement relationship over five-year strategic partnership
The Oxford AHSN already enjoys a very productive relationship with the global healthcare company Johnson & Johnson (J&J). J&J is one of the largest employers linked to healthcare in our region with its headquarters in High Wycombe.
Biomedical catalyst 2021: early and late stage awards
UK registered businesses can apply for a share of up to £18 million to develop innovative healthcare products, technologies and processes. This funding is from Innovate UK, part of UK Research and Innovation. Your project can address: -disease prevention and proactive management of health and chronic conditions -earlier and better detection and diagnosis of disease, leading to better patient outcomes -tailored treatments that either change the underlying disease or offer potential cures This list is not intended to be exhaustive. This competition combines the early and late-stage strands of the Biomedical Catalyst. Equality, diversity and inclusion (EDI) considerations are highly encouraged where appropriate in the proposal. Applications will continue to be assessed on their innovation merit, where innovation is defined as the potential for commercially successful exploitation of ideas. In applying to this competition, you are entering into a competitive process This competition closes Thursday 26 August 2021 11am UK time on the date of the deadline.
Eight ventures pitch for investment
On 27 November, eight innovative start-ups from the Oxford AHSN Accelerator, delivered by BioCity pr...